Progress in Mechanisms and Therapy of Chemotherapy-induced Thrombocytopenia

doi:10.3969/j.issn.1671-2587.2026.02.023

JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE ›› 2026, Vol. 28 ›› Issue (2): 293-299.DOI: 10.3969/j.issn.1671-2587.2026.02.023

Previous Articles Next Articles

Progress in Mechanisms and Therapy of Chemotherapy-induced Thrombocytopenia

ZHOU Zaixin, QIAN Baohua, GU Haihui

Department of Transfusion Medicine, The First Affiliated Hospital of Naval Medical University, Shanghai 200433

Received:2025-07-24 Accepted:2025-08-27 Online:2026-04-20 Published:2026-04-22

Abstract

Abstract: Platelet is one of the important components involved in the hemostatic process of the body, and chemotherapy-induced thrombocytopenia is one of the common side effects in the treatment of tumor patients. If PLT count cannot be recovered to 100×109/L, the next chemotherapy course often has to be interrupted, which seriously affects the therapeutic benefit. When the more severe grade 3~4 thrombocytopenia occurs, patients are at risk of severe bleeding, even life-threatening. Transfusion of apheresis platelets, human recombinant interleukin-11, and thrombopoietin have been widely used in the treatment of chemotherapy-induced thrombocytopenia, but the effectiveness of these strategies is not effective due to the patients' own underlying conditions. In this article, we review the latest clinical status, mechanism, and therapeutic benefits of chemotherapy-induced thrombocytopenia in recent years, we hope to explore more updated prevention and treatment techniques and measures.

Key words: Chemotherapy, Thrombocytopenia, Pathogenesis, Therapeutic measures

CLC Number:

R730.53R558+.2

ZHOU Zaixin, QIAN Baohua, GU Haihui. Progress in Mechanisms and Therapy of Chemotherapy-induced Thrombocytopenia[J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2026, 28(2): 293-299.

References

[1] 中国抗癌协会肿瘤临床化疗专业委员会,中国抗癌协会肿瘤支持治疗专业委员会. 中国肿瘤药物相关血小板减少诊疗专家共识(2023版)[J]. 中华医学杂志,2023, 103(33):2579-2590.
[2] 中国输血协会临床输血管理学专业委员会,中华医学会血液学分会,中国药师协会肿瘤药师分会. 靶向药物导致血液系统异常的输血与药物治疗中国专家共识[J]. 临床输血与检验, 2025, 27(1): 1-12.
[3] 中国输血协会人类组织抗原专业委员会,中国输血协会免疫血液学专业委员会. 免疫性血小板输注无效的判定及临床实践专家共识[J]. 临床输血与检验,2022,24(3): 273-278.
[4] 孙少勤. 重组人血小板生成素治疗血液肿瘤化疗所致血小板减少症疗效[J]. 临床输血与检验,2018,20(6):632-635.
[5] Gao A,Zhang L L,Zhong D S.Chemotherapy-induced thrombocytopenia: literature review[J]. Discov Oncol, 2023,14(1):10.
[6] Zwart N R K,Kok D E,Ariyaratne S N H,et al. Folate-associated DNA methylation and chemotherapy-induced toxicities in patients with colorectal cancer[J]. Mol Nutr Food Res,2025,69(14):e70127.
[7] Merza N,Farooqui S K,Dar S H,et al.Folfirinox vs. gemcitabine+nab-paclitaxel as the first-line treatment for pancreatic cancer: a systematic review and meta-analysis[J]. World J Oncol,2023,14(5):325-339.
[8] Zhang Y T,Yang F C,Wang J N,et al.Bevacizumab-induced immune thrombocytopenia in an ovarian cancer patient with mixed connective tissue disease: case report and literature review[J]. Front Immunol,2024,15: 1382964.
[9] Benkhadra R,Nayfeh T,Patibandla S K,et al.Systematic review and meta-analysis of cisplatin based neoadjuvant chemotherapy in muscle invasive bladder cancer[J]. Bladder Cancer,2022,8(1):5-17.
[10] Han X,Ge P,Liu S Y,et al.Efficacy and safety of bevacizumab in patients with malignant melanoma: a systematic review and PRISMA-compliant meta-analysis of randomized controlled trials and non-comparative clinical studies[J]. Front Pharmacol,2023,14:1163805.
[11] Song A B,Al-Samkari H.Chemotherapy-induced thrombocytopenia: modern diagnosis and treatment[J]. Br J Haematol,2025,206(4):1062-1066.
[12] Bakchoul T,Marini I.Drug-associated thrombocytopenia[J]. Hematology,2018,2018(1):576-583.
[13] Al-Samkari H,Kolb-Sielecki J,Safina S Z,et al.Avatrombopag for chemotherapy-induced thrombocytopenia in patients with non-haematological malignancies: an international,randomised,double-blind, placebo-controlled,phase 3 trial[J]. Lancet Haematol,2022,9(3): e179-e189.
[14] Shaw J L,Nielson C M,Park J K,et al.The incidence of thrombocytopenia in adult patients receiving chemotherapy for solid tumors or hematologic malignancies[J]. Eur J Haematol,2021,106(5):662-672.
[15] Kroll M H,Rojas-Hernandez C,Yee C.Hematologic complications of immune checkpoint inhibitors[J]. Blood,2022,139(25):3594-3604.
[16] Calvo R.Hematological side effects of immune checkpoint inhibitors: the example of immune-related thrombocytopenia[J]. Front Pharmacol,2019,10:454.
[17] Yamashita M,Dellorusso P V,Olson O C, et al.Dysregulated haematopoietic stem cell behaviour in myeloid leukaemogenesis[J]. Nat Rev Cancer,2020, 20(7):365-382.
[18] Dertinger S D,Avlasevich S L,Torous D K, et al.Persistence of cisplatin-induced mutagenicity in hematopoietic stem cells: implications for secondary cancer risk following chemotherapy[J]. Toxicol Sci, 2014,140(2):307-314.
[19] Chen Z,Ren X,Ren R M,et al.The combination of G-CSF and AMD3100 mobilizes bone marrow-derived stem cells to protect against cisplatin-induced acute kidney injury in mice[J]. Stem Cell Res Ther,2021,12(1):209.
[20] Al-Samkari H.Optimal management of chemotherapy-induced thrombocytopenia with thrombopoietin receptor agonists[J]. Blood Rev,2024,63:101139.
[21] Soff G,Leader A,Al-Samkari H,et al.Management of chemotherapy-induced thrombocytopenia: guidance from the ISTH Subcommittee on Hemostasis and Malignancy[J]. J Thromb Haemost,2024,22(1):53-60.
[22] Chai X,Li D G,Cao X L,et al.ROS-mediated iron overload injures the hematopoiesis of bone marrow by damaging hematopoietic stem/progenitor cells in mice[J]. Sci Rep,2015,5:10181.
[23] Abdelbaset-Ismail A,Ciechanowicz A K, Bujko K,et al.The Nox2-ROS-Nlrp3 inflammasome signaling stimulates in the hematopoietic stem/progenitor cells lipogenesis to facilitate membrane lipid raft formation[J]. Stem Cell Rev Rep,2023,19(1):92-103.
[24] Akunuru S,Geiger H.Aging,clonality,and rejuvenation of hematopoietic stem cells[J]. Trends Mol Med,2016, 22(8):701-712.
[25] Blank U,Karlsson S.TGF-β signaling in the control of hematopoietic stem cells[J]. Blood,2015,125(23):3542-3550.
[26] Gao X,Carpenter R S,Boulais P E,et al. Regulation of the hematopoietic stem cell pool by C-Kit-associated trogocytosis[J]. Science,2024,385(6709): eadp2065.
[27] Shin J Y,Hu W H,Naramura M,et al.High c-Kit expression identifies hematopoietic stem cells with impaired self-renewal and megakaryocytic bias[J]. J Exp Med,2014,211(2):217-231.
[28] Niazi V,Ghafouri-Fard S.Effect of bone marrow niche on hematopoietic stem cells[J]. Histochem Cell Biol, 2024,163(1):19.
[29] Penter L,Liu Y,Wolff J O,et al.Mechanisms of response and resistance to combined decitabine and ipilimumab for advanced myeloid disease[J]. Blood,2023,141(15):1817-1830.
[30] Tang C,Li M H,Chen Y L,et al.Chemotherapy-induced niche perturbs hematopoietic reconstitution in B-cell acute lymphoblastic leukemia[J]. J Exp Clin Cancer Res,2018,37(1):204.
[31] Rafieemehr H,Maleki Behzad M,Azandeh S,et al.Chemo/radiotherapy-induced bone marrow niche alterations[J]. Cancer Invest,2021,39(2):180-194.
[32] Lu R,Lin Q Y,Chen S,et al.Chemotherapy-induced thrombocytopenia and platelet transfusion in patients with diffuse large B-cell lymphoma[J]. Transl Cancer Res,2020,9(3):1640-1651.
[33] Erdem G U,Dogan M,Demirci N S,et al.Oxaliplatin-induced acute thrombocytopenia[J]. J Cancer Res Ther, 2016,12(2):509-514.
[34] Xue R Y,Li M,Zhang G,et al.GSDME-mediated pyroptosis contributes to chemotherapy-induced platelet hyperactivity and thrombotic potential[J]. Blood,2024, 144(25):2652-2665.
[35] Gao Z M,Qi N N,Qin X,et al.The addition of tislelizumab
to gemcitabine and cisplatin chemotherapy increases thrombocytopenia in patients with urothelial carcinoma: A single-center study based on propensity score matching[J]. Cancer Med,2023,12(24):22071-22080.
[36] Li J,Wang W Q,Jiang K P,et al.Risk factors of chemotherapy-induced thrombocytopenia after oxaliplatin-containing chemotherapy for gastrointestinal malignancies[J]. J Gastrointest Cancer,2024,55(3): 1144-1153.
[37] 肖函,王利. 肝硬化血小板减少的病理生理发生机制[J]. 实用肝脏病杂志,2019,22(4):462-465.
[38] Soff G,Leader A,Al-Samkari H,et al.Management of chemotherapy-induced thrombocytopenia: guidance from the ISTH Subcommittee on Hemostasis and Malignancy[J]. J Thromb Haemost,2024,22(1):53-60.
[39] 唐浩,桂嵘. 血小板输注疗效预测模型在血液肿瘤患者临床用血管理中的应用[J]. 临床输血与检验,2017,19(4): 313-316.
[40] Liu Z R,Wang Y X,Yan J X,et al.Efficacy and safety of recombinant human interleukin-11 in the treatment of acute leukaemia patients with chemotherapy-induced thrombocytopenia: A systematic review and meta-analysis[J]. J Eval Clin Pract,2020,26(1):262-271.
[41] Chen M T,Li L,Xia Q,et al.A real-world observation on thrombopoietic agents for patients with cancer treatment-induced thrombocytopenia in China: A multicenter,cross-sectional study[J]. Cancer,2024, 130(S8):1524-1538.
[42] Soff G A,Miao Y M,Bendheim G,et al.Romiplostim treatment of chemotherapy-induced thrombocytopenia[J]. J Clin Oncol,2019,37(31):2892-2898.
[43] Gurumurthy G,Kisiel F,Gurumurthy S,et al.Role of thrombopoietin receptor agonists in chemotherapy-induced thrombocytopenia: A meta-analysis[J]. J Oncol Pharm Pract,2025,31(1):4-11.
[44] Xia X H,Zhou H T,Zhang H,et al.Hetrombopag plus recombinant human thrombopoietin for chemotherapy-induced thrombocytopenia in patients with solid tumors[J]. Res Pract Thromb Haemost,2023,7(7):102231.
[45] Gernsheimer T B,Brown S P,Triulzi D J,et al.Prophylactic
tranexamic acid in patients with hematologic malignancy: a placebo-controlled, randomized clinical trial[J]. Blood, 2022,140(11):1254-1262.
[46] Nguyen V Q,Kristensen L,Frederiksen H.Acquired amegakaryocytic thrombocytopaenia after treatment with immune checkpoint inhibitor as part of neoadjuvant treatment in a patient with bilateral breast cancer[J]. BMJ Case Rep,2025,18(3):e263434.
[47] 陈信义,史哲新,侯丽. 肿瘤化疗相关性血小板减少症中医药防治专家共识[J]. 北京中医药,2021,40(5):451-455.
[48] 廖慧妍. 人参防治尼拉帕利所致骨髓抑制的作用和机理研究[D]. 广州:广州中医药大学,2022.
[49] 张院辉,范崇青,龚亚斌. 鹿血晶治疗恶性实体肿瘤化疗所致血小板减少症的随机对照研究[J]. 中医肿瘤学杂志, 2024,6(6):45-50.
[50] 王琴,葛云,徐东,等. 加味花生衣干预治疗吉西他滨联合顺铂方案引起血小板降低的效果及费用调查分析[J]. 现代肿瘤医学,2019,27(1):108-111.
[51] 沈君华. 升板方联合重组人白介素-2治疗化疗后血小板减少疗效观察[J]. 实用中医药杂志,2019,35(10):1241-1242.
[52] 孙静. 归脾汤治疗化疗相关性血小板减少症的临床研究[D]. 成都:成都中医药大学,2023.
[53] 陈娇健,王立森. 黄金昶刺血拔罐治疗化疗相关性血小板减少症经验[J]. 湖北中医杂志,2023,45(7):25-29.

Progress in Mechanisms and Therapy of Chemotherapy-induced Thrombocytopenia

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

About

Author

Journal

Access Statistics

Contact

[1]	LIU Yi, WEI Ting, LI Qingshan. Research Progress on Platelet Antibody Detection in Patients with Immune Thrombocytopenia [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2026, 28(2): 273-279.
[2]	WANG Xin, LI Yao, SHAN Zhuoyue, ZHAO Liyan. Research Progress on the Relationship between CD36 Antigen Deficiency and Clinical Blood Transfusion Safety [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2026, 28(2): 279-285.
[3]	XIE Wenju, FU Zike, WANG Qiushi. Progress in Fetal and Neonatal Alloimmune Thrombocytopenia [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2025, 27(6): 882-888.
[4]	MA Chunya, ZHANG Min, FU Lihui, ZHU Jianling, LUO Yuanyuan, GUAN Xiaozhen, YU Yang. Laboratory-based Diagnostic Investigation of Drug-induced Thrombocytopenia from Piperacillin-tazobactam Sodium [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2025, 27(2): 191-195.
[5]	ZHOU Xinhui, ZUO Bin, WANG Wen, HE Yang. The Association between Peripheral Lipid Profile and the Efficacy of Thrombopoietic Drugs in Patients with Immune Thrombocytopenia [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2025, 27(1): 115-120.
[6]	MING Jing, DING Kaiyang, HU Maogui, WANG Xinchen. Efficacy of Avatrombopag Combined with rhTPO for Thrombocytopenia Treatment in Patients with Hematologic Malignancies after Autologous Hematopoietic Stem Cell Transplantation [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2024, 26(6): 812-817.
[7]	WANG Xiao-yu, LIU Dan, ZHANG Xu-han, et al. A Clinical Study on the Induction Effect of Different doses of Idarubicin Combined with Cytarabine on Acute Myeloid Leukemia in Adults Under 60 Years of Age [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2022, 24(6): 791-797.
[8]	ZHA Yan-fang, YUAN Qing-feng, HU Shou-xin, et al. Effect of Postoperative Chemotherapy on Peripheral Blood Lymphocyte Subsets in Elderly Patients with HER2 Positive Gastric Cancer [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2022, 24(1): 93-96.
[9]	WANG Jing, WANG Cheng-yun, GU Ping, et al. Analysis of Related Factors between Platelet Antibody and Autoimmune Disorder in Children [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2021, 23(6): 708-710.
[10]	MA Ming-zi, WANG Qiu-shi, YU Yang. Retrospective Analysis of 36 Cases of Fetal Neonatal Alloimmune Thrombocytopenia in Chinese Population [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2021, 23(5): 585-592.
[11]	CHU Hai-liang, XING Ming-quan, GE Hong-feng. Analysis on Curative Effect of VCD Regimen Combined with Ubenimex on Multiple Myeloma and Factors Influencing Prognosis [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2021, 23(2): 216-221.
[12]	ZHENG Jing-xian, LI Xiao-hui, SUN Hong-qiang. Clinical Observation of Children with Immune Thrombocytopenia and the Study of the Effect of ANA/ANAs in the Disease [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2021, 23(2): 231-235.
[13]	CHENG Feng, XU Hong, XIAO Shu-xin, et al. Analysis on the Relationship between HPA-1-6/17 Gene Polymorphism and Genetic Susceptibility to Thrombocyto-penia in Qingdao [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2020, 22(5): 521-526.
[14]	YANG Mei, LUO Yu-qin, HE Chuan. Expression Level and Clinical Significance of sCXCL16 in Adult Primary Immune Thrombocytopenia [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2020, 22(4): 420-425.
[15]	HUANG Xue-yuan, CHEN Bing-yu, ZHOU Ming, et al. Clinical Significance of Platelet Antibody Detection——Based on Study of 2 338 Case from10 Institutions in China [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2020, 22(2): 113-117.